| Ag85B–ESAT-6 adjuvanted with IC31® promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naïve human volunteers JT van Dissel, SM Arend, C Prins, P Bang, PN Tingskov, K Lingnau, ... Vaccine 28 (20), 3571-3581, 2010 | 263 | 2010 |
| First-in-human trial of the post-exposure tuberculosis vaccine H56: IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults AKK Luabeya, BMN Kagina, MD Tameris, H Geldenhuys, ST Hoff, Z Shi, ... Vaccine 33 (33), 4130-4140, 2015 | 200 | 2015 |
| Ag85B–ESAT-6 adjuvanted with IC31® promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or … JT Van Dissel, D Soonawala, SA Joosten, C Prins, SM Arend, P Bang, ... Vaccine 29 (11), 2100-2109, 2011 | 178 | 2011 |
| Antigen availability shapes T cell differentiation and function during tuberculosis AO Moguche, M Musvosvi, A Penn-Nicholson, CR Plumlee, H Mearns, ... Cell host & microbe 21 (6), 695-706. e5, 2017 | 164 | 2017 |
| A double-blind, randomized trial of IV immunoglobulin treatment in acute optic neuritis HG Roed, A Langkilde, F Sellebjerg, M Lauritzen, P Bang, A Mørup, ... Neurology 64 (5), 804-810, 2005 | 159 | 2005 |
| Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo … Sonya Abraham*, Helene B Juel*, Peter Bang, Hannah M Cheeseman, Rebecca B ... Lancet Infectious Disease, 0, 2019 | 150 | 2019 |
| Human plasma‐derived mannose‐binding lectin: a phase I safety and pharmacokinetic study H Valdimarsson, T Vikingsdottir, P Bang, S Saevarsdottir, JE Gudjonsson, ... Scandinavian journal of immunology 59 (1), 97-102, 2004 | 136 | 2004 |
| A phase 2b randomized, controlled trial of the efficacy of the GMZ2 malaria vaccine in African children SB Sirima, B Mordmüller, P Milligan, UA Ngoa, F Kironde, F Atuguba, ... Vaccine 34 (38), 4536-4542, 2016 | 116 | 2016 |
| Low levels of mannose‐binding lectin do not affect occurrence of severe infections or duration of fever in acute myeloid leukaemia during remission induction therapy OJ Bergmann, M Christiansen, I Laursen, P Bang, NE Hansen, ... European journal of haematology 70 (2), 91-97, 2003 | 97 | 2003 |
| First in humans: A new molecularly defined vaccine shows excellent safety and strong induction of long-lived Mycobacterium tuberculosis-specific Th1-cell like … THM Ottenhoff, TM Doherty, JT van Dissel, P Bang, K Lingnau, I Kromann, ... Human Vaccines 6 (12), 1007-1015, 2010 | 89 | 2010 |
| Non-clinical efficacy and safety of HyVac4: IC31 vaccine administered in a BCG prime–boost regimen YAW Skeiky, J Dietrich, TM Lasco, K Stagliano, V Dheenadhayalan, ... Vaccine 28 (4), 1084-1093, 2010 | 89 | 2010 |
| Safety and Immunogenicity of H1/IC31®, an Adjuvanted TB Subunit Vaccine, in HIV-Infected Adults with CD4+ Lymphocyte Counts Greater than 350 cells/mm3: A … K Reither, L Katsoulis, T Beattie, N Gardiner, N Lenz, K Said, E Mfinanga, ... PloS one 9 (12), e114602, 2014 | 78 | 2014 |
| Development and preclinical safety evaluation of a new therapeutic HIV-1 vaccine based on 18 T-cell minimal epitope peptides applying a novel cationic adjuvant CAF01 A Fomsgaard, I Karlsson, G Gram, C Schou, S Tang, P Bang, I Kromann, ... Vaccine 29 (40), 7067-7074, 2011 | 69 | 2011 |
| Diagnosis of latent tuberculosis infection in healthy young adults in a country with high tuberculosis burden and BCG vaccination at birth AF Dagnew, J Hussein, M Abebe, M Zewdie, A Mihret, A Bedru, ... BMC research notes 5 (1), 1-7, 2012 | 48 | 2012 |
| H1: IC31 vaccination is safe and induces long-lived TNF-α+ IL-2+ CD4 T cell responses in M. tuberculosis infected and uninfected adolescents: a randomized trial H Mearns, HD Geldenhuys, BM Kagina, M Musvosvi, F Little, F Ratangee, ... Vaccine 35 (1), 132-141, 2017 | 45 | 2017 |
| The pharmacokinetic profile of plasma-derived mannan-binding lectin in healthy adult volunteers and patients with Staphylococcus aureus septicaemia P Bang, I Laursen, K Thornberg, J Schierbeck, B Nielsen, H Valdimarsson, ... Scandinavian journal of infectious diseases 40 (1), 44-48, 2008 | 35 | 2008 |
| A Phase I/II randomized trial of H56: IC31 vaccination and adjunctive cyclooxygenase-2-inhibitor treatment in tuberculosis patients S Jenum, K Tonby, CS Rueegg, M Rühwald, MP Kristiansen, P Bang, ... Nature Communications 12 (1), 6774, 2021 | 32 | 2021 |
| A phase I, open-label trial on the safety and immunogenicity of the adjuvanted tuberculosis subunit vaccine H1/IC31® in people living in a TB-endemic area J Hussein, M Zewdie, L Yamuah, A Bedru, M Abebe, AF Dagnew, ... Trials 19, 1-10, 2018 | 24 | 2018 |
| Development, manufacturing and characterization of a highly purified, liquid immunoglobulin g preparation from human plasma IA Laursen, L Blou, JS Sullivan, P Bang, F Balstrup, G Houen Transfusion Medicine and Hemotherapy 41 (3), 205-212, 2014 | 23 | 2014 |
| Antiviral Innate Immune Activation in HIV-Infected Adults Negatively Affects H1/IC31-Induced Vaccine-Specific Memory CD4+ T Cells N Lenz, T Schindler, BM Kagina, JD Zhang, T Lukindo, M Mpina, P Bang, ... Clinical and vaccine immunology 22 (7), 688-696, 2015 | 14 | 2015 |
